# A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

> **NCT06047860** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Refractory Tumor

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** PD-1/PD-L1 inhibitor
- **DRUG:** Granulocyte-macrophage colony-stimulating factor subcutaneous injection
- **DRUG:** Interleukin 2 subcutaneous injection
- **DRUG:** Endostatin

## Key facts

- **NCT ID:** NCT06047860
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-16
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047860, "A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06047860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*